335 related articles for article (PubMed ID: 23094795)
1. Cytotoxic effects of Jay Amin hydroxamic acid (JAHA), a ferrocene-based class I histone deacetylase inhibitor, on triple-negative MDA-MB231 breast cancer cells.
Librizzi M; Longo A; Chiarelli R; Amin J; Spencer J; Luparello C
Chem Res Toxicol; 2012 Nov; 25(11):2608-16. PubMed ID: 23094795
[TBL] [Abstract][Full Text] [Related]
2. Molecular Signatures Associated with Treatment of Triple-Negative MDA-MB231 Breast Cancer Cells with Histone Deacetylase Inhibitors JAHA and SAHA.
Librizzi M; Caradonna F; Cruciata I; Dębski J; Sansook S; Dadlez M; Spencer J; Luparello C
Chem Res Toxicol; 2017 Dec; 30(12):2187-2196. PubMed ID: 29129070
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.
Guan P; Sun F; Hou X; Wang F; Yi F; Xu W; Fang H
Bioorg Med Chem; 2012 Jun; 20(12):3865-72. PubMed ID: 22579621
[TBL] [Abstract][Full Text] [Related]
4. Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.
Zhang Y; Feng J; Jia Y; Wang X; Zhang L; Liu C; Fang H; Xu W
J Med Chem; 2011 Apr; 54(8):2823-38. PubMed ID: 21476600
[TBL] [Abstract][Full Text] [Related]
5. Biological Effect of a Hybrid Anticancer Agent Based on Kinase and Histone Deacetylase Inhibitors on Triple-Negative (MDA-MB231) Breast Cancer Cells.
Librizzi M; Spencer J; Luparello C
Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27483253
[TBL] [Abstract][Full Text] [Related]
6. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
[TBL] [Abstract][Full Text] [Related]
7. New aryldithiolethione derivatives as potent histone deacetylase inhibitors.
Tazzari V; Cappelletti G; Casagrande M; Perrino E; Renzi L; Del Soldato P; Sparatore A
Bioorg Med Chem; 2010 Jun; 18(12):4187-94. PubMed ID: 20576572
[TBL] [Abstract][Full Text] [Related]
8. Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity.
Salmi-Smail C; Fabre A; Dequiedt F; Restouin A; Castellano R; Garbit S; Roche P; Morelli X; Brunel JM; Collette Y
J Med Chem; 2010 Apr; 53(8):3038-47. PubMed ID: 20218673
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity.
Chetan B; Bunha M; Jagrat M; Sinha BN; Saiko P; Graser G; Szekeres T; Raman G; Rajendran P; Moorthy D; Basu A; Jayaprakash V
Bioorg Med Chem Lett; 2010 Jul; 20(13):3906-10. PubMed ID: 20605448
[TBL] [Abstract][Full Text] [Related]
10. Benzothiazole-containing hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
Oanh DT; Hai HV; Park SH; Kim HJ; Han BW; Kim HS; Hong JT; Han SB; Hue VT; Nam NH
Bioorg Med Chem Lett; 2011 Dec; 21(24):7509-12. PubMed ID: 22036991
[TBL] [Abstract][Full Text] [Related]
11. Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy.
Jazirehi AR
Anticancer Drugs; 2010 Oct; 21(9):805-13. PubMed ID: 20679890
[TBL] [Abstract][Full Text] [Related]
12. The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.
Shultz M; Fan J; Chen C; Cho YS; Davis N; Bickford S; Buteau K; Cao X; Holmqvist M; Hsu M; Jiang L; Liu G; Lu Q; Patel C; Suresh JR; Selvaraj M; Urban L; Wang P; Yan-Neale Y; Whitehead L; Zhang H; Zhou L; Atadja P
Bioorg Med Chem Lett; 2011 Aug; 21(16):4909-12. PubMed ID: 21742496
[TBL] [Abstract][Full Text] [Related]
13. Novel cinnamyl hydroxyamides and 2-aminoanilides as histone deacetylase inhibitors: apoptotic induction and cytodifferentiation activity.
Valente S; Tardugno M; Conte M; Cirilli R; Perrone A; Ragno R; Simeoni S; Tramontano A; Massa S; Nebbioso A; Miceli M; Franci G; Brosch G; Altucci L; Mai A
ChemMedChem; 2011 Apr; 6(4):698-712. PubMed ID: 21374822
[TBL] [Abstract][Full Text] [Related]
14. Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects.
Liao V; Liu T; Codd R
Bioorg Med Chem Lett; 2012 Oct; 22(19):6200-4. PubMed ID: 22932316
[TBL] [Abstract][Full Text] [Related]
15. The discovery of colchicine-SAHA hybrids as a new class of antitumor agents.
Zhang X; Zhang J; Tong L; Luo Y; Su M; Zang Y; Li J; Lu W; Chen Y
Bioorg Med Chem; 2013 Jun; 21(11):3240-4. PubMed ID: 23602523
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits anti-inflammatory activities through induction of mitochondrial damage and apoptosis in activated lymphocytes.
Shi ZJ; Ouyang DY; Zhu JS; Xu LH; He XH
Int Immunopharmacol; 2012 Apr; 12(4):580-7. PubMed ID: 22369900
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and antitumor activity of novel diaryl ether hydroxamic acids derivatives as potential HDAC inhibitors.
Zhu Y; Chen X; Wu Z; Zheng Y; Chen Y; Tang W; Lu T
Arch Pharm Res; 2012 Oct; 35(10):1723-32. PubMed ID: 23139122
[TBL] [Abstract][Full Text] [Related]
18. Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo.
Park KC; Kim SW; Park JH; Song EH; Yang JW; Chung HJ; Jung HJ; Suh JS; Kwon HJ; Choi SH
Cancer Sci; 2011 Feb; 102(2):343-50. PubMed ID: 21159061
[TBL] [Abstract][Full Text] [Related]
19. The role of oxidative stress in apoptosis induced by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in human colon adenocarcinoma HT-29 cells.
Portanova P; Russo T; Pellerito O; Calvaruso G; Giuliano M; Vento R; Tesoriere G
Int J Oncol; 2008 Aug; 33(2):325-31. PubMed ID: 18636153
[TBL] [Abstract][Full Text] [Related]
20. Combined effects of sulindac and suberoylanilide hydroxamic acid on apoptosis induction in human lung cancer cells.
Seo SK; Jin HO; Lee HC; Woo SH; Kim ES; Yoo DH; Lee SJ; An S; Rhee CH; Hong SI; Choe TB; Park IC
Mol Pharmacol; 2008 Mar; 73(3):1005-12. PubMed ID: 18156316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]